Nevertheless, to elucidate the effect of HCV superinfection in HCC, we specifically compared the clinical characteristics and prognosis between 42 HBV-HCC patients and 16 HBCV-HCC patients, all of whom use the same driver mutation, HBV-TERT, to reduce tumor heterogeneity between HBV-HCC and HBCV-HCC. The gene discussed is TERT; the disease is neoplasm.